Cargando…

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen

The combination of luteinizing hormone-releasing hormone analogs (LHRHa) with tamoxifen is used as a standard postoperative adjuvant therapy in patients with hormone receptor-positive/premenopausal breast cancer. Long-acting LHRHa formulations offer advantages in terms of patient convenience. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Young-jin, Wu, Zhen-Yu, Kim, Hee jeong, Lee, Jong Won, Chung, Il Yong, Kim, Jisun, Lee, Sae Byul, Son, Byung Ho, Kim, Sung-Bae, Jung, Jae Ho, Gong, Gyungyub, Ahn, Sei-Hyun, Ko, BeomSeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604376/ https://www.ncbi.nlm.nih.gov/pubmed/33154830 http://dx.doi.org/10.4048/jbc.2020.23.e57

Ejemplares similares

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Estradiol: micrograms or milligrams
por: Kirk, Jeremy M W, et al.
Publicado: (2016)

Clinical development of the GnRH agonist leuprolide acetate depot
por: Chwalisz, Kristof
Publicado: (2022)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016)

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
por: Spitz, A, et al.
Publicado: (2012)

Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer
por: Lee, Young-Won, et al.
Publicado: (2023)

Myocardial Infarction in a Premenopausal Woman on Leuprolide Therapy
por: Perez, Irving E., et al.
Publicado: (2015)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study
por: Lee, Peter A, et al.
Publicado: (2011)

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
por: Baek, Soo Yeon, et al.
Publicado: (2019)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

Magnetic resonance imaging based 3-dimensional printed breast surgical guide for breast-conserving surgery in ductal carcinoma in situ: a clinical trial
por: Wu, Zhen-Yu, et al.
Publicado: (2020)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Delayed Oral Estradiol Combined with Leuprolide Increases Endometriosis-Related Pain
por: Hurst, Bradley S., et al.
Publicado: (2000)

Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study
por: Kim, Myung Soo, et al.
Publicado: (2021)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
por: Tunn, Ulf W
Publicado: (2011)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma
por: Yoon, Tae In, et al.
Publicado: (2023)

Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial
por: Najafi, Safa, et al.
Publicado: (2023)

Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution’s experience
por: Alqudaihi, Heba Mohammad Abdulla, et al.
Publicado: (2022)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Salivary Duct Cancer Metastasis Mimicking Primary Breast Cancer: A Case Report and Review
por: Alzuhair, Aisha M., et al.
Publicado: (2019)

Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155
por: Kim, Sinae, et al.
Publicado: (2021)

Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies
por: Spitz, Aaron, et al.
Publicado: (2016)

Leuprolide acetate induces structural and functional recovery of injured spinal cord in rats
por: Díaz Galindo, Carmen, et al.
Publicado: (2015)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment
por: Lee, Han Shin, et al.
Publicado: (2021)

In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system
por: Mashayekhi, Roya, et al.
Publicado: (2013)

Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
por: Ryu, Ki-Jin, et al.
Publicado: (2022)

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
por: Lee, Maria, et al.
Publicado: (2020)

Breast-conserving surgery with 3D-printed surgical guide: a single-center, prospective clinical study
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
por: Lee, Sae Byul, et al.
Publicado: (2021)

Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study
por: Kim, Hakyoung, et al.
Publicado: (2022)

No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery
por: Yoon, Tae In, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l5qknktjtnu4r8iomalb6l93rv